Prophytaxie de l'ostéoporose cortisonique: qui, quand et quoi [Prevention of cortisone-induced osteoporosis: who, when and what?]


Autoria(s): Aubry-Rozier B.; Lamy O.; Dudler J.
Data(s)

2010

Resumo

Glucocorticoid-induced osteoporosis is a known phenomenon with already an increased fracture risk at 2.5 mg of prednisone daily over 3 months. This risk appears to be independent of bone densitometry results, in contradiction with published guidelines. With the creation of our Department of Musculoskeletal Medicine, we wanted to edict clear recommendations for the prevention of steroid-induced osteoporosis. In addition to the standard general measures to prevent osteoporosis and calcium and vitamin D supplementation, we advocate the use of a specific treatment for osteoporosis in all cases when the duration of corticosteroid therapy is not strictly limited and shorter than 3 months. Bisphosphonates are the treatment of choice, while the analogue of parathyroid hormone remains an alternative in cases with a very high fracture risk.

Identificador

http://serval.unil.ch/?id=serval:BIB_14DB30821BE6

isbn:1660-9379[print], 1660-9379[linking]

pmid:20218181

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 6, no. 235, pp. 307-313

Palavras-Chave #Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents/administration & dosage; Anti-Inflammatory Agents/adverse effects; Cortisone/administration & dosage; Cortisone/adverse effects; Drug Administration Schedule; Fractures, Bone/epidemiology; Fractures, Bone/prevention & control; Humans; Middle Aged; Osteoporosis/chemically induced; Osteoporosis/prevention & control
Tipo

info:eu-repo/semantics/article

article